Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Tg Therapeutics, Inc.

Rhizen Pharmaceuticals Sa

Rhizen Pharmaceuticals Na

Peter Sportelli

Michael S Weiss

Hari P Miskin

Swaroop K V S Vakkalanka

Michael Joseph Weiss

George Costas Avgerinos

Jill A Myers

Patrick Michael Hossler

Yune Z Kunes

Sri Hari Pandurang Miskin

Hari Miskin

Swaroop Kvs Vakkalanka

Swaroop KVS Vakkalanka

Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Anti-CD20 antibody compositions

Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

Highly effective combinations of a compound of formula A (a PI3K&#x3b4; selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K&#x3b4; and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

Highly effective combinations of a compound of formula A (a PI3K&#x3b4; selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K&#x3b4; and/or CD20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Growing community of inventors

New York, NY, United States of America

Peter Sportelli